Soleakhena Ken

Journal: Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)

Published: December 01, 2020

Semi-automatic segmentation of whole-body images in longitudinal studies.

Journal: Biomedical physics & engineering express

Published: August 18, 2020

Determination of paramagnetic ferrous gel sensitivity in low energy x-ray beam produced by a miniature accelerator.

Journal: PloS one

Published: November 21, 2018

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.

Journal: BMC cancer

Published: May 19, 2018

Clinical outcome and deep learning imaging characteristics of patients treated by radio-chemotherapy for a "molecular" glioblastoma.

Clinical outcome and deep learning imaging characteristics of patients treated by radio-chemotherapy for a "molecular" glioblastoma.

New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling.

New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling.

Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial).

Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial).

Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results.

Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results.

Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.

Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.

Is pre-radiotherapy metabolic heterogeneity of glioblastoma predictive of progression-free survival?

Is pre-radiotherapy metabolic heterogeneity of glioblastoma predictive of progression-free survival?

Radiomics-Based Detection of Radionecrosis Using Harmonized Multiparametric MRI.

Radiomics-Based Detection of Radionecrosis Using Harmonized Multiparametric MRI.

Quality control of 3D MRSI data in glioblastoma: Can we do without the experts?

Quality control of 3D MRSI data in glioblastoma: Can we do without the experts?

Expanding the medical physicist curricular and professional programme to include Artificial Intelligence.

Expanding the medical physicist curricular and professional programme to include Artificial Intelligence.

Semi-automatic segmentation of whole-body images in longitudinal studies.

Semi-automatic segmentation of whole-body images in longitudinal studies.

Determination of paramagnetic ferrous gel sensitivity in low energy x-ray beam produced by a miniature accelerator.

Determination of paramagnetic ferrous gel sensitivity in low energy x-ray beam produced by a miniature accelerator.

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.

Hypofractionated Stereotactic Re-irradiation and  Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results.

Hypofractionated Stereotactic Re-irradiation and  Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results.